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Abstract
Background: Pulmonary malignancy is one of the most frequent and fatal can-
cers in older patients. As data on lower respiratory tract infection (LRTI) and the
outcome of lung cancer are scarce, our objective was to determine the impact of
LRTI on therapeutic possibilities and one-year mortality.
Methods: Patients undergoing bronchoscopy in 2017 who had bronchial micro-
bial sampling at the time of the lung cancer diagnosis (n = 143) were included.
Group 1 (LRTI+) included patients with confirmed infection (n = 74) while
Group 2 (LRTI-) included patients without infection (n = 69). Clinical character-
istics, pathogen profile and one-year survival were analyzed.
Results: Age, gender, TNM stage, histology type, comorbidities or underlying lung
disease did not differ among groups. The most common LRTI pathogens included
aerobic (n = 49), anaerobic (n = 14) and fungal (n = 26) infections. Chemo/-
immune/target therapy alone, or in combination with radiotherapy were significantly
less frequently used, whilst palliative care was more common in Group 1 (LRTI+).
Multiple pathogen LRTI patients were significantly older, less frequently diagnosed
with adenocarcinoma and had worse performance status compared to solitary patho-
gen LRTI patients. One-year median survival was 274 days (235 vs. 305 days Group
1 vs. Group 2). Risk factors for increased one-year mortality included performance
status ≥2 (OR 30.00, CI 95% 5.23–313.00), performance status 1 (OR 11.87, CI 95%
4.12–33.78), male gender (OR 4.04, CI 2.03–8.04), LRTI with multiple pathogens
(OR 2.72, CI 1.01–6.81) and nonadenocarcinoma histology (OR 2.26, CI 1.15–4.56).
Conclusion: LRTIs in lung cancer patients, especially multiple pathogen infec-
tions, are associated with less oncotherapeutic possibilities and significant risk for
lower one-year median survival.
Key Points
Significant findings of the study
Patients with LRTI less frequently had adencocarcinoma, sig-
nificantly worse ECOG performance status withholding several
treatment possibilities and lower one-year survival. Patients with
multiple pathogen LRTI were less eligible for oncotherapy and
had significantly increased risk of one-year mortality.
What this study adds
More attention should be given to LRTI lung cancer
patients and the pathogen profile described in our series
could assist with empiric treatment selection. Treatable
threats are important elements to improve survival of this
special patient population.
Introduction
Lung cancer is one of the leading causes of malignancy-
associated mortality worldwide.1 The prevalence in older
age has risen considerably in the past decade,2 with more
than 2 000 000 patients recognized yearly with pulmonary
malignancy.3
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Lung cancer is often asymptomatic in the early stages;
on the other hand, most cases are diagnosed only when the
disease is at an advanced stage.4 No established screening
strategies are available; however, the results of the NEL-
SON trial, using a low dose CT, are promising for the
future.5
Advanced disease, older age and comorbidities often
make histological verification difficult and may also be
associated with less favorable treatment options.6 Lung
cancer often develops in damaged lungs (e.g., chronic
obstructive lung disease, emphysema, idiopathic pulmo-
nary fibrosis [IPF]) and underlying lung diseases might
make diagnosis and treatment even more difficult.7,8 In
addition to lung disease, numerous factors can additionally
predispose lung cancer patients to develop lower respira-
tory tract infection (LRTI), including damage to anatomi-
cal barriers during invasive procedures.9 With subtle or
absent respiratory symptoms, the diagnosis of infection is
often delayed, which can readily lead to increased morbid-
ity and mortality especially for elderly individuals.10–12
Despite the high mortality rate of lung cancer, additional
treatable threats should be considered when treating
patients, particularly with extensive disease. In this study,
we aimed to determine LRTI in Hungarian lung cancer




The medical records of 966 patients undergoing bronchos-
copy at Semmelweis University, Department of
Pulmonology in the year 2017 were reviewed. All patients
who underwent bronchoscopy for microbiological sam-
pling (n = 648) were selected, out of whom all with con-
firmed pulmonary malignancy (n = 143) were included in
this retrospective analysis. The selection of the study popu-
lation is summarized in Fig 1.
Two groups were compared: Group 1, (n = 74) con-
sisting of patients with concomitant lower respiratory tract
infection (LRTI+) at the time of the diagnosis, and Group
2 (LRTI-; n = 69). Demographic information (age, gender),
smoking habits, stage (TNM classification of malignant
tumors), body mass index (BMI), underlying lung disease
(presence of chronic obstructive pulmonary (COPD)
and/or interstitial lung disease (ILD), anatomical localiza-
tion of the cancer, ECOG (Eastern Cooperative Oncology
Group) performance status, comorbidities, peripheral
blood neutrophil/lymphocyte ratio (NLR), tumor histology
were summarized. Forced vital capacity (FVC), forced
expiratory volume in one second (FEV1), FEV1/ FVC|) was
measured by means of electronic spirometer and
plethysmography (PDD-301/s, Piston, Budapest, Hungary)
according to the American Thoracic Society guidelines.13
Three technically acceptable maneuvers were performed
and the highest used.
Additionally, cancer therapy, including curative intent
surgery/radiotherapy, chemotherapy and/or radiotherapy
as well as the best supportive care were analyzed. All treat-
ment decisions were made at the multidisciplinary tumor
board according to national regulations and ESMO
(European Society for Medical Oncology) guidelines.14–16
All patients were followed for at least one year. One-year
survival was assessed in all patients and the results of the
groups were analyzed.
Lower respiratory tract infection
Bronchoscopies with microbiological test results from
bronchial lavage were selected. Microbial analysis was
more frequently performed in bronchoscopic procedures in
patients with purulent endobronchial mucus, which may
have contributed to some extent to selection bias. The sam-
ples were analyzed for aerobic and anaerobic bacteria, fun-
gal and Mycobacterium infections. Infections appearing in












146 patients with 
malignancy at care in 
pulmonology
3 patients excluded
3 without pulmonary 
malignancy
143 patients with 
pulmonary malignancy




74 patients with lower 
respiratory tract infection 
(LRTI+)
29 patients with multiple 
pathogen LRTI
45 patients with solitary 
pathogen LRTI
Figure 1 Selection of the study population.
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further areas, such as global septicemia or urinary tract
infection, were not considered for the current research.
LRTI was confirmed when samples contained pathogens of
colony forming units (CFU) ≥102, while lower CFU was
considered as potential upper-airway contamination. Infec-
tions with samples positive for only one pathogen were
acknowledged as solitary pathogen infections. LRTI with at
least two microorganisms were determined as multiple
pathogen LRTI. All clinical data, oncotherapy and one-year
survival were additionally assessed in solitary pathogen and
multiple pathogen subgroups of Group 1 (LRTI+).
Statistical analysis
Data are reported as means  SEM or median (range). Sta-
tistical analysis was performed with the GraphPad software
(Graph Pad Prism 5.0 by Graph Pad Software Inc., San
Diego, USA). Normally distributed data were analyzed by
an unpaired t-test, for categorical data, the Chi-square test
was used. Survival was analyzed with the Kaplan Meier
test. Risk factors for one-year mortality were calculated
with determining odds ratios (Graph Pad Prism 5.0 by
Graph Pad Software Inc., San Diego, USA and IBM SPSS,




Our analysis included slightly more men than women, and
these were mostly ever-smokers (Table 1.). Histology dis-
tribution, anatomical location, and underlying lung dis-
eases were not different between the groups and TNM
stages were similarly distributed. Most of the patients were
discovered in more advanced stages, not eligible for cura-
tive intent therapies, which was similar in both groups.
Most patients had an ECOG performance status of 0–1;
however, we could see significantly more patients with the
best performance state in Group 2 (LRTI-). No differences
in the number of comorbidities were noted. Significantly
higher NLR was observed in Group 1 (LRTI+).
In Group 1 (LRTI+) the pathogen profile is summarized
according to the histology type in Table 2. Aerobic, anaero-
bic and fungal infections did not differ, but significantly
more solitary pathogens were noted in adenocarcinoma
patients. Most common solitary pathogens in Group
1 (LRTI+) included Candida albicans (n = 19),
H. influenzae (n = 15), S. aureus (n = 13), S. pneumoniae
(n = 10), Enterobacter spp. (n = 10), P. aeruginosa (n = 7)
and other pathogens (n = 42). Isolates of multiple patho-
gen LRTI were similarly distributed, and included Candida
albicans (n = 14), S. pneumoniae (n = 7), S. aureus (n = 7),
P. aeruginosa (n = 6), H. influenzae (n = 6) and other
pathogens (n = 31); although there were proportionally
more Candida albicans, S. pneumonia and P. aeruginosa
infections detected. The percentage of H. influenzae was
notably lower than in the solitary pathogen LRTI individ-
uals (8.45% vs. 20%).
Oncotherapy possibilities are summarized in Table 3.
Curative intent interventions were not different between
groups; less than 15% were eligible. Chemo/immune/target
therapy alone or in combination with radiotherapy were
significantly less frequent in Group 1 (LRTI+) as compared
to Group 2 (LRTI-). Conversely, significantly more patients
in Group 1 (LRTI+) could only receive the best supportive
care (BSC) as compared to Group 2 (LRTI-). In general,
nearly one-quarter of the patients were not eligible for pal-
liative oncotherapeutic interventions.
The one-year median survival for all patients was
274 days, lower for Group 1 (LRTI+) with 235 days as
compared to Group 2 (LRTI-) where it was 305 days.
Kaplan Meier analysis did not show any statistically signifi-
cant differences between the groups (P = 0.244, HR: 1292
[95% CI: 0.84–1.99], Fig 2).
Between the subgroups, made according to the presence
of solitary or multiple pathogens, patients in the latter
group were significantly older and had worse ECOG per-
formance status (Table 1). Significantly less adenocarci-
noma was noted in this subgroup and the curative intent
interventions were less common in these cases. Signifi-
cantly more patients could only receive BSC compared to
solitary pathogen LRTI (Table 1). Lung cancer patients
with solitary pathogen LRTI had longer median one-year
survival as compared to patients with multiple pathogens
(306 vs. 146 days, HR: 1.57 [95% CI: 0.87–2.99], P = 0,318;
Fig 2). Patients with multiple pathogen infections had
shorter median one-year survival than lung cancer patients
in Group 2 (LRTI-) (146 vs. 305 days, HR: 1.67 [95% CI:
0.98–3.23], P = 0.057).
Odds ratio analysis data are presented in Table 4. Signif-
icantly higher risk could be observed for one-year mortality
in case of performance status ≥2, male gender, LRTI with
multiple pathogens and nonadenocarcinoma histology.
Discussion
In our study, lung cancer treatment possibilities and one-
year survival were analyzed according to the presence of
LRTI at the time of bronchoscopy intervention. Interaction
of LRTI and lung cancer outcome data is scarce, and our
data demonstrated worse outcome in patients with lung
malignancies, having LRTI at diagnosis. In the case of
LRTI patient’s ECOG performance status was significantly
worse; consequently, patients had less therapeutic possibili-
ties. This is in line with the Italian survey, confirming the
Thoracic Cancer 10 (2019) 1819–1826 © 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd 1821
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most common cause of patient exclusion from first-line
chemotherapy, which is the poor ECOG performance sta-
tus (2–4).17 The ECOG performance status is a crucial pre-
dictive factor when allowing for treatment with
chemotherapy, and the higher the number is connected
with shorter survival as also noted in previous studies18,19
and confirmed in our analysis.
Similarly to other researches, the NLR was higher in
patients with lung malignancy, associated with LRTI and
lower in those with noninfectious cases.20 High NLR at
diagnosis is an accepted prognostic marker of worse prog-
nosis and therapy response for patients with lung
cancer.21–23 As infections are often associated with high
neutrophil count it could have contributed to the worse
outcome in Group 1 (LRTI+) patients, most pronounced
in patients with multiple pathogen infections.
The incidence of adenocarcinoma was the highest in our
study population in agreement with international litera-
ture.4 Adenocarcinoma histology was associated with a
more favorable outcome in our study population. Lung
adenocarcinoma is mainly observed as a peripheral lesion,
but in advanced stages, it also appears centrally,24 similarly
to the other histological subtypes.25 Central carcinoma is
readily associated with bronchial stricture and underlying
pneumonia, which can advance in lung atelectasis. Conse-
quently, microorganism colonization may evolve to infec-
tion. These known differences in the location could have
contributed to the higher number of solitary pathogens
(80.65% vs. 46.51%) in adenocarcinoma patients; however,
in our analysis, the locations of the tumors did not notably
differ in the case of LRTI.
Patients with LRTI had worse one-year survival as com-
pared to patients without an infection and significant
increase of risk of one-year mortality. This is in line with
previous observations, where patients with multiple patho-
gen LRTI got shorter median survival than patients with
the solitary pathogen LRTI (8.0 vs. 15.0 months,
P = 0.003).26
The lungs although previously considered sterile in
health are regularly colonized with varied communities of
microbes from the oropharynx and other locations. The
most common Bacteroidetes and Firmicutes are the
Prevotella, Veillonella and Streptococcus spp. Microbiota of
the lung which mostly correspond to those of the mouth
than of other body sites. In cases of respiratory tract
inflammation, intra-alveolar catecholamines and inflamma-
tory cytokines advance the growth of selected bacterial spe-
cies (e.g., P. aeruginosa, S. pneumoniae, Staphylococcus
aureus, Burkholderia cepacia complex).27
The most predominant pathogen in our lung cancer
patients were Candida albicans, pursued by H. influenzae,
S. aureus, S. pneumoniae and Enterobacter spp. These path-
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but the incidence of the microorganisms is different in
recent studies, where the isolates of Enterobacter spp.
(40.86%), followed by S. aureus (21.51%), H. influenzae
(16.13%) and S. pneumoniae (7.53%) were recorded.28 The
nonfermenting Gram-negative bacteria were Pseudomonas
spp. (6.45%) and Acinetobacter spp. (3.23%). Among fun-
gal species, the most common was Candida albicans
(63.77%).28,29
Infections increase the incidence of several malignancies
(e.g., Human papillomavirus types 6 and 11 DNA
sequences in cervical cancers, Helicobacter pylori infection
in colorectal carcinoma).30,31 Lung cancer often evolves in
damaged lungs (e.g., COPD, emphysema, IPF).7,8 In these
lung diseases, mucociliary abnormality can grant mutagens
from the smoke or further air pollution longer contact
period at these locations, promoting the progress of pul-
monary malignancy formation.32 Constant irritation, cau-
sed by airway obstruction and the imbalance among
oxidants and antioxidants may lead to DNA changes.33
The incidence of pulmonary malignancy in patients with
IPF (4.8% to 48%) is significantly higher than in patients
without IPF (2.0% to 6.4%).34,35 The mechanism of
increased cancer development in IPF might be associated
with increased inflammatory reaction, cell damage, abnor-
mal fibroblast production and the activation of specific sig-
naling pathways (e.g., Wnt/β-catein).36–39 In our data set,
about half of the patients had a significant underlying lung
disease (COPD/IPF); however, this was not associated with
differences in patients’ characteristics of histology in the
presence of LRTI.
In conclusion, LRTI, detected in bronchial samples at
the time of diagnosis of lung malignancies influences the
treatment options and outcome of these patients. Our data
confirmed that LRTI+ patients had a worse ECOG perfor-
mance status, withholding several treatment possibilities
and so resulting in lower one-year survival. Patients with
multiple pathogen LRTI were particularly less eligible for
oncotherapy; however, no differences in stage, cancer his-
tology subtype, gender or age were noted.
Our data emphasize that more attention should be given
to LRTI and its treatment in lung cancer patients. The
pathogen profile described in our series may assist with the
selection of empiric treatment and hopefully decrease the
observed risk of one-year mortality. Treatable threats are
Table 2 LRTI pathogens in bronchoscopic samples at the time of cancer diagnosis
Pathogen
Group 1 LRTI








cancer (n = 9)
P-
value
Aerobic (n [%]) 49 (55.06) 21 (60.00) 16 (59.26) 7 (58.33) 5 (33.33) 0.32
Anaerobic (n [%]) 14 (15.73) 5 (14.29) 4 (14.81) 2 (16.66) 3 (20.00) 0.96
Fungal (n [%]) 26 (29.21) 9 (25.71) 7 (25.93) 3 (25.00) 7 (46.66) 0.44
Solitary pathogen
(n [%])
45 (60.81) 25 (80.65) 12 (50.00) 5 (50.00) 3 (33.33) 0.02
Multiple pathogen
(n [%])
29 (39.19) 6 (19.35) 12 (50.00) 5 (50.00) 6 (66.66)
P-value was calculated for different cancer types in Group 1. LRTI, Lower respiratory tract infections; n, number; SCLC, small cell lung cancer.






















19 (13.29) 11 (14.86) 8 (11.60) 0.56 10 (22.22) 1 (3.45) 0.02
Chemo−/immune−/target
therapy (n [%])
62 (43.36) 25 (33.78) 37 (53.62) 0.02 15 (33.33) 10 (34.48) 0.91
Chemo + radiotherapy (n [%]) 16 (11.19) 4 (5.41) 12 (17.39) 0.02 2 (4.44) 2 (6.90) 0.64
Radiotherapy (n [%]) 5 (3.49) 5 (6.76) 0 Not valid 2 (4.44) 3 (10.34) 0.32
BSC (n [%]) 34 (23.78) 24 (32.43) 10 (14.49) 0.01 11 (24.44) 13 (44.83) 0.06
Lost from medical attendance
(n [%])
7 (4.89) 5 (6.76) 2 (2.90) 0.28 5 (11.11) 0 Not valid
P-value was calculated for Group 1 vs. Group 2 and for Solitary vs. multiple pathogen. BSC, best supportive care; LRTI, lower respiratory tract infec-
tions; n, number.
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important elements to improve therapy and survival of this
special patient population.
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